Variational AI, a Vancouver-based Healthcare Tech Company, advances Generative AI Drug Discovery by designing novel small molecules for therapeutic needs. Its collaborations with major pharma partners showcase its impact, while leveraging Variational Autoencoders to generate innovative, data-driven solutions that transform medicine and accelerate therapeutic development.
Variational AI takes advantage of cutting-edge machine learning and generative models to simplify the design of small-molecule therapy. Its technology allows for quicker and more efficient discovery processes, thus providing biopharma partners with more options, scalability, and lower risk during the early stages of development.
The firm collaborates with the top pharmaceutical companies to transform the standard operations and give the big ideas a shorter time to come out. By means of data-driven innovation, Variational AI brings about powerful solutions that not only foster the progress of therapeutics but also contribute to better healthcare for the people worldwide.
| Legal Name | Variational AI Inc. |
| Headquarters | Vancouver, British Columbia, Canada |
| Business Model | B2B |
| Founding Date | 2019 |
| No. of Employees | Approx 20 (As of 2025) |
Variational AI offers a generative AI platform, de novo compound generation, lead optimization, collaborative discovery programs, and AI-enhanced screening libraries. Their solutions include novel small-molecule design, multi-property optimization, target-specific molecule generation, custom model tuning, and early drug discovery support.
| Handol Kim | Co-Founder & Chief Executive Officer |
| Jason Rolfe, PhD | Co-Founder & Chief Technology Officer |
| Ali Saberali, PhD | Co-Founder & Head of Platform |
| Peter Guzzo, PhD | EVP, Head of Drug Discovery |
| Roslynn Drewitt-Lange | Vice President, Finance & Operations |
Variational AI generates revenue via pharma collaborations, milestone payments, licensing, and co-development agreements, focusing on AI-driven molecule design for efficient discovery.
Client Segments: Biopharmaceutical companies and research organizations interested in generative AI–driven small-molecule discovery.
Target Companies: Pharma R&D groups, biotech firms, and organizations focused on early-stage drug discovery using AI.
Target Users: Drug discovery scientists and computational chemistry teams using foundation models for molecule generation.
Target Geography: Based in Vancouver, Canada, with global reach through collaborations.